This is a summary of the European public assessment report (EPAR) for Natpar. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Natpar. For practical information about using Natpar, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
Therapeutic Area (MeSH)
ATC Code
H05AA03
ATC Item
parathyroid hormone
Pharmacotherapeutic Group
Calcium homeostasis
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| parathyroid hormone | N/A | Parathyroid hormone |
EMA Name
Natpar
Medicine Name
Natpar
Aliases
N/ANo risk management plan link.
